Unternehmen COSMO Pharmaceuticals SA Swiss Exchange
Aktien
LU1202320294
Pharmazeutika
Schlusskurs
Andere Börsenplätze
|
||
- CHF | - |
Kurzporträt
Umsatz nach Geschäftsbereich
CHF in Millionen | 2021 | Gewichtung | 2022 | Gewichtung | Delta |
---|---|---|---|---|---|
Own Products
52,0
%
| 43 | 60,6 % | 53 | 52,0 % | +25.05% |
Licence Fees, Up-front Fees and Milestones
23,8
%
| 6 | 8,5 % | 24 | 23,8 % | +310.51% |
Generic Products, Specialty Drugs and Related Services
12,9
%
| 14 | 19,4 % | 13 | 12,9 % | -3.41% |
Royalties
9,7
%
| 6 | 8,6 % | 10 | 9,7 % | +63.17% |
Other
1,6
%
| 2 | 2,9 % | 2 | 1,6 % | -17.40% |
Umsatz je Region
CHF in Millionen | 2021 | Gewichtung | 2022 | Gewichtung | Delta |
---|---|---|---|---|---|
Italy
100,0
%
| 70 | 100,0 % | 102 | 100,0 % | +45.72% |
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
Chief Executive Officer | 61 | 01.01.06 | |
Niall Donnelly
DFI | Director of Finance/CFO | 52 | 01.06.16 |
Chief Tech/Sci/R&D Officer | 54 | - | |
Luigi Longo
CTO | Chief Tech/Sci/R&D Officer | 45 | 01.06.05 |
Davide Malavasi
CTO | Chief Tech/Sci/R&D Officer | 51 | 01.09.11 |
Marco Lecchi
COO | Chief Operating Officer | 60 | 01.01.01 |
Hazel Winchester
IRC | Investor Relations Contact | 53 | 10.01.22 |
Nhan Ngo Dinh
PRN | Corporate Officer/Principal | 45 | - |
Biagio Viganò
HRO | Human Resources Officer | 50 | - |
Diana Harbort
PRN | Corporate Officer/Principal | 57 | 01.01.22 |
Aufsichtsräte
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
David W Maris
BRD | Director/Board Member | 57 | 28.05.21 |
Founder | 69 | 01.01.97 | |
Director/Board Member | 64 | 01.01.06 | |
Director/Board Member | 69 | 01.04.12 | |
Director/Board Member | 65 | 01.03.16 | |
Chief Executive Officer | 61 | 01.01.06 |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 1 | 17 543 522 | 7 805 026 ( 44,49 %) | 1 490 681 ( 8,497 %) | 44,49 % |
Unternehmensbesitz
Name | Aktien | % | Bewertung |
---|---|---|---|
1 283 390 | 7,32% | 101 593 999 $ |
Unternehmenskontakt
Cosmo Pharmaceuticals NV
Riverside II Sir John Rogerson's Quay
2, Dublin
+353 1 817 0370
http://www.cosmopharma.comKonzerngesellschaften
Name | Kategorie und Branche |
---|---|
Pharmaceuticals: Major
| |
Cosmo Technologies Ltd.
Cosmo Technologies Ltd. Pharmaceuticals: MajorHealth Technology Part of Cosmo Pharmaceuticals NV, Cosmo Technologies Ltd. is an Irish pharmaceutical company that manufactures and distributes pharmaceutical products. The private company is based in Dublin, Ireland. Cosmo Technologies was acquired by Salix Pharmaceuticals Ltd. from Cosmo Pharmaceuticals SA. |
Pharmaceuticals: Major
|
Granell Strategic Investment Fund Ltd.
|
Investment Managers
|
Sektor
Umsatz nach Geschäftsbereich
% 1. Jan. | Kap. | |
---|---|---|
+26.08% | 662 Mrd. | |
+21.85% | 546 Mrd. | |
-4.77% | 359 Mrd. | |
+16.97% | 323 Mrd. | |
+5.69% | 290 Mrd. | |
+13.68% | 234 Mrd. | |
+3.65% | 198 Mrd. | |
-11.12% | 194 Mrd. | |
+8.08% | 167 Mrd. |
- Börse
- Aktien
- A2AJ68 Aktie
- Aktie
- Unternehmen COSMO Pharmaceuticals SA